Bin Zheng

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Immune Response

Top Venues

Cancer research communications

Nature nanotechnology

Nature communications

Nature metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Yang Chen, Chaochao Wang, Yelin Wu, Ya Wang, Yun Meng, Fan Wu, Huilin Zhang, Yuen Yee Cheng, Xingwu Jiang, Jieyun Shi, Huiyan Li, Peiran Zhao, Jinfeng Wu, Bin Zheng, Dayong Jin, Wen-Bo Bu
Nutrient-delivery and metabolism reactivation therapy for melanoma. Nature nanotechnology (2024)
Paul B Chapman, Mark G Klang, Michael A Postow, Alexander N Shoushtari, Ryan J Sullivan, Jedd D Wolchok, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K Callahan, Bin Zheng, Jonathan H Zippin
Phase Ib trial of phenformin in patients with V600-mutated melanoma receiving dabrafenib and trametinib. Cancer research communications (2023)
Hongyun Zhao, Da Teng, Lifeng Yang, Xincheng Xu, Jiajia Chen, Tengjia Jiang, Austin Y Feng, Yaqing Zhang, Dennie T Frederick, Lei Gu, Li Cai, John M Asara, Marina Pasca di Magliano, Genevieve M Boland, Keith T Flaherty, Kenneth D Swanson, David Liu, Joshua D Rabinowitz, Bin Zheng
Myeloid-derived itaconate suppresses cytotoxic CD8 + T cells and promotes tumour growth. Nature metabolism (2022)
Zhaowei Chu, Lei Gu, Yeguang Hu, Xiaoyang Zhang, Man Li, Jiajia Chen, Da Teng, Man Huang, Che-Hung Shen, Li Cai, Yeguang Hu, Yifeng Qi, Zhixin Niu, Austin Feng, Songmei Geng, Dennie T Frederick, Emma Specht, Adriano Piris, Ryan J Sullivan, Keith T Flaherty, Genevieve M Boland, Katia Georgopoulos, David Liu, Yang Shi, Bin Zheng
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. Nature communications 13 (1) (2022)